Summit Therapeutics Reports Q1 Earnings Beat, Highlights Major ASCO Plenary Session for Ivonescimab OS Data

summarizeSummary

Summit Therapeutics reported a Q1 non-GAAP net loss of $(0.15) per share, beating consensus estimates, and announced that overall survival data for its ivonescimab HARMONi-6 trial will be presented at the ASCO 2026 Plenary Session.

check_boxKey Events

• Q1 Earnings Beat

  Reported a non-GAAP net loss of $(0.15) per basic and diluted share for Q1 2026, which was narrower than the consensus estimate of $(0.18) per share.

• Major ASCO Plenary Session Presentation

  Overall survival data from the Phase III HARMONi-6 trial (conducted in China by Akeso) for ivonescimab will be featured in the Plenary Session of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026. Plenary sessions are reserved for high-impact clinical data.

• Ivonescimab BLA Accepted by FDA

  The U.S. FDA accepted Summit's Biologics License Application (BLA) for ivonescimab in January 2026, with a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.

• HARMONi-3 Interim Analysis Continues

  An early interim PFS analysis for the squamous cohort of the HARMONi-3 study recommended continuation as planned by the Independent Data Monitoring Committee (iDMC), with no safety concerns noted. Final PFS data is expected in the second half of 2026.

auto_awesomeAnalysis

Summit Therapeutics reported a narrower-than-expected non-GAAP net loss for Q1 2026, beating analyst estimates. The filing also provides significant clinical updates for its lead drug candidate, ivonescimab, including the upcoming presentation of overall survival data from the HARMONi-6 trial at the ASCO 2026 Plenary Session, a highly prestigious platform for clinical data. The FDA's acceptance of the Biologics License Application (BLA) for ivonescimab with a PDUFA date in November 2026 further de-risks the regulatory pathway. While the company continues to burn cash at a high rate, its cash reserves remain substantial, providing runway for ongoing clinical development. The combination of a financial beat and major clinical catalysts makes this a positive and important update for investors.